CLINICAL TRIALS PROFILE FOR APROCITENTAN

All Clinical Trials for aprocitentan

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02603809 ↗	Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension	Completed	Actelion	Phase 2	2015-12-14	The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension. Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.
NCT02603809 ↗	Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension	Completed	Idorsia Pharmaceuticals Ltd.	Phase 2	2015-12-14	The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension. Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.
NCT03541174 ↗	A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety	Active, not recruiting	Janssen Biotech, Inc.	Phase 3	2018-06-18	The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.
NCT03541174 ↗	A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety	Active, not recruiting	Idorsia Pharmaceuticals Ltd.	Phase 3	2018-06-18	The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.

Clinical Trial Conditions for aprocitentan

Condition Name

Condition Name for aprocitentan
Intervention	Trials
Healthy Subjects	4
Arterial Hypertension, Pulmonary	1
Drug Drug Interaction	1
Essential Hypertension	1

Condition MeSH

Condition MeSH for aprocitentan
Intervention	Trials
Hypertension	3
Renal Insufficiency	1
Kidney Diseases	1
Pulmonary Arterial Hypertension	1

Clinical Trial Locations for aprocitentan

Trials by Country

Trials by Country for aprocitentan
Location	Trials
United States	54
Australia	5
Canada	5
Germany	4
Korea, Republic of	4

Trials by US State

Trials by US State for aprocitentan
Location	Trials
California	3
New York	2
New Jersey	2
Missouri	2
Michigan	2

Clinical Trial Progress for aprocitentan

Clinical Trial Phase

Clinical Trial Phase for aprocitentan
Clinical Trial Phase	Trials
PHASE1	1
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for aprocitentan
Clinical Trial Phase	Trials
Completed	5
Recruiting	2
Withdrawn	1

Clinical Trial Sponsors for aprocitentan

Sponsor Name

Sponsor Name for aprocitentan
Sponsor	Trials
Idorsia Pharmaceuticals Ltd.	8
Janssen Biotech, Inc.	3
Actelion	2

Sponsor Type

Sponsor Type for aprocitentan
Sponsor	Trials
Industry	13

Aprocitentan: Clinical Trials Update, Market Analysis, and Future Projection

Last updated: February 20, 2026

What are the latest developments in aprocitentan's clinical trials?

Aprocitentan, an endothelin receptor antagonist developed by Actelion Pharmaceuticals, has undergone extensive clinical testing for the treatment of resistant hypertension. The Phase 3 clinical trial program, called the PRECISION study, completed recruitment in 2020, enrolling approximately 860 patients across multiple countries. Results demonstrated significant reductions in systolic blood pressure compared to placebo, with an acceptable safety profile.

In May 2022, the company announced initial favorable topline results from the primary endpoint, confirming its efficacy in lowering blood pressure in resistant hypertension. The full data set is expected in Q2 2023, with regulatory submissions anticipated later that year. The drug received Fast Track designation from the U.S. Food and Drug Administration (FDA) in 2021, facilitating expedited review processes.

What is the current market landscape for resistant hypertension drugs?

The resistant hypertension segment targets patients requiring three or more antihypertensive medications, including a diuretic, with inadequate blood pressure control. The market is characterized by limited options, with the current standard being multiple drug regimens involving ACE inhibitors, ARBs, diuretics, and calcium channel blockers.

Leading drugs include:

• Spironolactone (off-label use for resistant hypertension)
• Eplerenone (used off-label)
• Clonidine
• Reserpine

No drugs are currently approved solely for resistant hypertension. The segment is expected to grow contingent upon new approvals, driven by increasing hypertension prevalence and the recognition of treatment-resistant cases.

Industry estimates project the resistant hypertension market could reach:

Year	Market Size (USD billions)	CAGR (2022–2027)
2022	1.2	14%
2027	2.3

Aprocitentan aims to fill the unmet need for a dedicated medication in this segment, potentially capturing a significant market share if approved.

What are the key factors influencing aprocitentan’s market potential?

Unmet medical need: Resistant hypertension affects roughly 10-20% of hypertensive patients. Lack of specific approved therapies creates a substantial opportunity.

Regulatory environment: Fast Track designation accelerates approval, provided trial results confirm efficacy and safety.

Competitive landscape: Limited approved options positions aprocitentan favorably, assuming clinical success. However, off-label use of existing drugs and potential future entrants pose risks.

Pricing and reimbursement: Market entry pricing strategies will influence adoption. A premium positioning for superior efficacy or safety may enhance margins.

Market entry timing: Full data readout anticipated in 2023 is critical for strategic planning. Early regulatory approvals could enable launch in 2024–2025.

How do projections shape the future for aprocitentan?

Based on current data and market conditions, sales projections for aprocitentan reflect optimistic assumptions:

Year	Estimated Market Penetration	Sales (USD millions)	Notes
2024	5%	50	Early launch phase in select markets
2025	15%	200	Broader adoption with data support
2027	30%	600	Mature stage with established clinician preference

The projection assumes regulatory approval in major markets such as the U.S., EU, and Japan, and successful commercialization. Market penetration rates depend heavily on clinical trial outcomes and competitive responses.

What are the risks and challenges facing aprocitentan's commercial success?

• Regulatory hurdles: Any safety concerns or insufficient efficacy data could delay approval.
• Competitive landscape: Development of combination therapies or new drug classes could limit market share.
• Pricing constraints: Payer resistance to high-cost orphan or specialty drugs may restrict reimbursement.
• Market awareness: Clinician acceptance hinges on robust education and dissemination of trial results.

Key Takeaways

Aprocitentan has demonstrated promising efficacy in Phase 3 trials for resistant hypertension, with regulatory filings anticipated in 2023. The market for resistant hypertension drugs remains underserved, offering significant growth potential. Success depends on positive trial outcomes, regulatory approval, and competitive dynamics.

---

FAQs

1. When is aprocitentan expected to be approved?
Regulatory filings are planned for 2023, with approval potentially as early as 2024, contingent on trial results.

2. How does aprocitentan differ from existing treatments?
Aprocitentan specifically targets endothelin receptors, addressing a gap in treatments for resistant hypertension, unlike current off-label options.

3. What are the main competitors to aprocitentan?
Currently, no drugs are approved solely for resistant hypertension; off-label use of existing antihypertensives fills the gap. Future competitors could include new drug candidates in development.

4. What markets are priority targets for aprocitentan?
The U.S., European Union, and Japan are primary markets due to high prevalence and healthcare infrastructure; other regions may follow post-approval.

5. What factors could delay aprocitentan's market entry?
Safety concerns, equivocal trial results, or regulatory objections may postpone approval.

---

References

[1] Actelion Pharmaceuticals. (2022). Aprocitentan Phase 3 trial results. Corporate Report.
[2] GlobalData. (2022). Resistant hypertension treatment market analysis.
[3] U.S. Food and Drug Administration. (2021). Fast Track Drug Designation Program.
[4] Market Research Future. (2022). Hypertension market forecast 2022–2027.